| Title | MHC2TA single nucleotide polymorphism and genetic risk for autoimmune adrenal insufficiency. | | Author(s) | Ghaderi M, Gambelunghe G, Tortoioli C, Brozzetti A, Jatta K, Gharizadeh B, De Bellis A, Pecori Giraldi F, Terzolo M, Betterle C, Falorni A | | Institution | Department of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden (MG); the Department of Internal Medicine, Section of Internal Medicine and Endocrine & Metabolic Sciences, University of Perugia, Italy (GG, CT, AB, AF); the Division of Biomedicine, Department of Clinical Medicine, University of Örebro, Örebro, Sweden (KJ); the Stanford Genome Technology Center, Stanford University, Palo Alto, CA, USA (BG); the Department of Clinical and Experimental Medicine and Surgery F. Magrassi, A. Lanzara, Second University of Naples, Italy (ADB); the Chair of Endocrinology, University of Milan, Ospedale San Luca, Istituto Auxologico Italiano IRCCS, Milan, Italy (FPG); the Medicina Interna I, Department of Clinical and Biological Sciences, University of Torino, ASO San Luigi, Orbassano, Italy (MT); and the Department of Medical and Surgical Sciences, University of Padova, Padova, Italy (CB). | | Source | J Clin Endocrinol Metab 2006 Jul 18. | | Abstract | Context: The polymorphism of class II HLA genes modulates the genetic risk for several endocrine autoimmune diseases. The constitutive class II expression on antigen presenting cells is under the control of the MHC class II transactivator (CIITA), encoded by the MHC2TA gene, which is mapped to chromosome 16p13. The MHC2TA-168 A-->G SNP (rs3087456) has been suggested to confer susceptibility to some autoimmune diseases.
Design: With the aim of testing whether this MHC2TA SNP is independently associated with autoimmune Addison's disease (AAD) and/or modulates the genetic risk conferred by DRB1-DQA1-DQB1 haplotypes, we analyzed DNA samples from 128 AAD patients and 406 healthy control subjects, from continental Italy.
Results: Frequency of allele G of MHC2TA was significantly increased among AAD patients (39% alleles), compared with 29% in healthy controls (P = 0.003). Similarly, the frequency of AG+GG genotypes was significantly higher among AAD patients than among healthy control subjects, in both a co-dominant (P = 0.012) and a G dominant model (P = 0.018). Multivariate logistic regression analysis showed that MHC2TA AG+GG continued to be positively associated with genetic risk for AAD (P = 0.028, OR=1.72, 95%CI=1.06-2.78), after correction for DRB1*03-DQA1*0501-DQB1*0201, DRB1*04 (not 0403)-DQA1*0301-DQB1*0302 and DRB1*0403. Similar results were obtained when the number of G alleles was included in the model (P = 0.004; OR=1.65, 95% CI: 1.17-2.32).
Conclusions: Our study provides the first demonstration of the association of the polymorphism of the MHC2TA gene with genetic risk for AAD that appears to be independent from the well known association with the polymorphism of HLA class II genes. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 16849401 |
|
